GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » Cyclically Adjusted PB Ratio

XORTX Therapeutics (TSXV:XRTX) Cyclically Adjusted PB Ratio : 1.18 (As of Jun. 07, 2024)


View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-07), XORTX Therapeutics's current share price is C$3.26. XORTX Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was C$2.76. XORTX Therapeutics's Cyclically Adjusted PB Ratio for today is 1.18.

The historical rank and industry rank for XORTX Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSXV:XRTX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.43
Current: 1.27

During the past years, XORTX Therapeutics's highest Cyclically Adjusted PB Ratio was 1.43. The lowest was 0.00. And the median was 0.00.

TSXV:XRTX's Cyclically Adjusted PB Ratio is ranked better than
57.49% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs TSXV:XRTX: 1.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

XORTX Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was C$1.161. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$2.76 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


XORTX Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for XORTX Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Cyclically Adjusted PB Ratio Chart

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only - - - - -

XORTX Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.81

Competitive Comparison of XORTX Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, XORTX Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Cyclically Adjusted PB Ratio falls into.



XORTX Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

XORTX Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.26/2.76
=1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XORTX Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, XORTX Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.161/126.2576*126.2576
=1.161

Current CPI (Mar. 2024) = 126.2576.

XORTX Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201405 0.000 99.394 0.000
201408 0.000 99.315 0.000
201411 0.000 99.078 0.000
201502 1.304 99.078 1.662
201505 1.120 100.263 1.410
201508 0.441 100.579 0.554
201511 2.280 100.421 2.867
201602 2.034 100.421 2.557
201605 1.652 101.765 2.050
201608 1.271 101.686 1.578
201611 2.346 101.607 2.915
201702 0.924 102.476 1.138
201705 0.688 103.108 0.842
201708 0.325 103.108 0.398
201711 0.218 103.740 0.265
201803 1.679 105.004 2.019
201806 1.254 105.557 1.500
201809 0.779 105.636 0.931
201812 0.532 105.399 0.637
201903 0.274 106.979 0.323
201906 0.035 107.690 0.041
201909 -0.170 107.611 -0.199
201912 -0.358 107.769 -0.419
202003 2.804 107.927 3.280
202006 2.589 108.401 3.015
202009 2.149 108.164 2.508
202012 1.643 108.559 1.911
202103 3.317 110.298 3.797
202106 3.142 111.720 3.551
202109 -3.977 112.905 -4.447
202112 11.709 113.774 12.994
202203 9.415 117.646 10.104
202206 8.429 120.806 8.809
202209 7.236 120.648 7.572
202212 5.691 120.964 5.940
202303 6.201 122.702 6.381
202306 4.917 124.203 4.998
202309 4.120 125.230 4.154
202312 3.116 125.072 3.146
202403 1.161 126.258 1.161

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XORTX Therapeutics  (TSXV:XRTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


XORTX Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics (TSXV:XRTX) Business Description

Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Executives
Allen Warren Davidoff Director, Senior Officer